Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
berzosertib (M6620)
i
Other names:
M6620, VX-970, M 6620, VX970, VX 970, VE822, VE-822
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(19)
News
Trials
Company:
EMD Serono, Vertex
Drug class:
ATR inhibitor
Related drugs:
‹
AZD6738 (16)
BAY 1895344 (13)
VE-821 (6)
SC0245 (2)
ATG-018 (1)
QL-VIII-58 (1)
M1774 (1)
ART0380 (0)
ATRN-119 (0)
IMP9064 (0)
RP-3500 (0)
M4344 (0)
AZD6738 (16)
BAY 1895344 (13)
VE-821 (6)
SC0245 (2)
ATG-018 (1)
QL-VIII-58 (1)
M1774 (1)
ART0380 (0)
ATRN-119 (0)
IMP9064 (0)
RP-3500 (0)
M4344 (0)
›
Associations
(19)
News
Trials
VERI cancer hierarchy
Reset Filters
ATM deletion
Colorectal Cancer
ATM deletion
Colorectal Cancer
M6620
Sensitive: C3 – Early Trials
M6620
Sensitive
:
C3
M6620
Sensitive: C3 – Early Trials
M6620
Sensitive
:
C3
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
M6620
Sensitive: C3 – Early Trials
M6620
Sensitive
:
C3
M6620
Sensitive: C3 – Early Trials
M6620
Sensitive
:
C3
TP53 mutation
Gastric Cancer
TP53 mutation
Gastric Cancer
M6620
Sensitive: C3 – Early Trials
M6620
Sensitive
:
C3
M6620
Sensitive: C3 – Early Trials
M6620
Sensitive
:
C3
TP53 mutation
Gastroesophageal Junction Adenocarcinoma
TP53 mutation
Gastroesophageal Junction Adenocarcinoma
M6620
Sensitive: C3 – Early Trials
M6620
Sensitive
:
C3
M6620
Sensitive: C3 – Early Trials
M6620
Sensitive
:
C3
CHEK2 mutation
Tongue Carcinoma
CHEK2 mutation
Tongue Carcinoma
ABT-888 + M6620
Sensitive: C4 – Case Studies
ABT-888 + M6620
Sensitive
:
C4
ABT-888 + M6620
Sensitive: C4 – Case Studies
ABT-888 + M6620
Sensitive
:
C4
ATM mutation
Breast Cancer
ATM mutation
Breast Cancer
ABT-888 + M6620
Sensitive: C4 – Case Studies
ABT-888 + M6620
Sensitive
:
C4
ABT-888 + M6620
Sensitive: C4 – Case Studies
ABT-888 + M6620
Sensitive
:
C4
ARID1A 548fs
Ovarian Cancer
ARID1A 548fs
Ovarian Cancer
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
ARID1A 756fs
Ovarian Cancer
ARID1A 756fs
Ovarian Cancer
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
ARID1A deletion
Colorectal Cancer
ARID1A deletion
Colorectal Cancer
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
MYB-NFIB fusion
Adenoid Cystic Carcinoma
MYB-NFIB fusion
Adenoid Cystic Carcinoma
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
SLFN11 underexpression
Small Cell Lung Cancer
SLFN11 underexpression
Small Cell Lung Cancer
M6620 + lurbinectedin
Sensitive: D – Preclinical
M6620 + lurbinectedin
Sensitive
:
D
M6620 + lurbinectedin
Sensitive: D – Preclinical
M6620 + lurbinectedin
Sensitive
:
D
ATR mutation
Colorectal Cancer
ATR mutation
Colorectal Cancer
M6620 + SNB-101
Sensitive: D – Preclinical
M6620 + SNB-101
Sensitive
:
D
M6620 + SNB-101
Sensitive: D – Preclinical
M6620 + SNB-101
Sensitive
:
D
ATR mutation
Colorectal Cancer
ATR mutation
Colorectal Cancer
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
VHL deletion
Clear Cell Renal Cell Carcinoma
VHL deletion
Clear Cell Renal Cell Carcinoma
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
ERCC5 overexpression
Small Cell Lung Cancer
ERCC5 overexpression
Small Cell Lung Cancer
M6620 + lurbinectedin
Sensitive: D – Preclinical
M6620 + lurbinectedin
Sensitive
:
D
M6620 + lurbinectedin
Sensitive: D – Preclinical
M6620 + lurbinectedin
Sensitive
:
D
SLFN11 overexpression
Small Cell Lung Cancer
SLFN11 overexpression
Small Cell Lung Cancer
M6620 + lurbinectedin
Sensitive: D – Preclinical
M6620 + lurbinectedin
Sensitive
:
D
M6620 + lurbinectedin
Sensitive: D – Preclinical
M6620 + lurbinectedin
Sensitive
:
D
TP53 deletion
Acute Lymphocytic Leukemia
TP53 deletion
Acute Lymphocytic Leukemia
M6620 + BAY2402234
Sensitive: D – Preclinical
M6620 + BAY2402234
Sensitive
:
D
M6620 + BAY2402234
Sensitive: D – Preclinical
M6620 + BAY2402234
Sensitive
:
D
ATM deletion
Bladder Cancer
ATM deletion
Bladder Cancer
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
M6620
Sensitive: D – Preclinical
M6620
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login